Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2005

View Archived Issues

Iptakalim holds promise for pulmonary hypertension treatment

Profile of novel antipsychotic agent SLV-314, a D2 antagonist/serotonin reuptake inhibitor

LT-1951 reported safe in patients undergoing CABG surgery

Studies confirm the antitumor effects of INGN-241 in metastatic melanoma

New data on the efficacy of aselizumab in psoriasis

A sunflower oleodistillate shows promise in the treatment of atopic dermatitis

CombinatoRx and Angiotech sign research and license agreement

Dainippon and Sumitomo create Dainippon Sumitomo Pharma

MGI Pharma completes acquisition of Guilford

Salix and InKine complete merger

Innogenetics extends collaboration with IDM Pharma

Elusys to study Anthim for anthrax in phase I study

Depomed delivers notice of breach to Biovail

Astellas and MerLion sign drug discovery agreement

Phase I protocol submitted for Stem Cells Therapeutics' stroke program

Phase II studies planned for Oxycyte

N-Butyrylglucosamine shows efficacy in experimental models of arthritis

Novel agents for diabetes and related complications reported in recent patent literature

Humira approved for new rheumatoid arthritis indication and psoriatic arthritis

European approval for shorter course of Peg-Intron and Rebetol

Long-term effects and safety of ambrisentan in PAH patients

Approvable letter for Zelapar

Ispronicline improves cognition in patients with mild impairment

Innovive to begin phase I trials with INNO-105 for solid malignancies

Recent Theravance patent discloses novel 5-HT4 receptor agonists for gastrointestinal disorders

Novel therapeutics for cardiovascular diseases reported